Apellis Pharmaceuticals (APLS) Stock Analysis 2026 | Is APLS Still a Buy After 134% Rally?

Apellis Pharmaceuticals (NASDAQ: APLS) stock has surged more than 134% in one year and investors are asking: is APLS still a buy in 2026?

In this video, we break down Apellis Pharmaceuticals stock using revenue growth, profitability, valuation metrics, analyst price targets, risks, and future upside potential.

APLS is gaining attention in the biotech sector due to strong growth from SYFOVRE and EMPAVELI. But after such a massive rally, can the stock continue higher?

In This Video:

✔ APLS stock latest price analysis
✔ Revenue and earnings review
✔ Balance sheet strength
✔ Analyst targets
✔ Risks and opportunities
✔ APLS stock prediction 2026
✔ Buy, Hold, or Sell?

If you enjoy stock market analysis, biotech stocks, growth investing, and Nasdaq stock picks, subscribe for more videos.

Disclaimer:

This video is for educational purposes only and not financial advice. Always do your own research before investing.

#APLS #ApellisPharmaceuticals #StockAnalysis

Видео Apellis Pharmaceuticals (APLS) Stock Analysis 2026 | Is APLS Still a Buy After 134% Rally? канала GM Stock Investing